Compositions comprising a prostaglandin for treating neuropsychiatric conditions
The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).
1. A method of ameliorating or palliating a subject having bipolar disorder, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, is administered in an amount sufficient to inhibit glycogen synthase kinase-3 (GSK-3) in the subject.
3. The method of claim 2 , wherein the latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, is administered in an amount sufficient to produce a steady state plasma concentration of from about 1 pg/ml to about 10 ng/ml.
4. The method of claim 1 , wherein the latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, is deuterium-enriched and/or nitrosylated.
5. The method of claim 1 , wherein the latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of from about 0.00001% to about 0.2% (w/v).
6. The method of claim 1 , wherein the subject is a human.
7. The method of claim 1 , wherein the pharmaceutical composition is administered intramuscularly, intravenously, intradermally, intraarterially, intraperitoneally, intranasally, intravitreally, intrarectally, subcutaneously, subconjunctivally, intravesicularly, mucosally, intraocularally, orally or topically; or by inhalation, infusion, continuous infusion, or in cremes or lipid compositions.
8. The method of claim 1 , wherein the pharmaceutical composition comprises a pharmaceutically acceptable carrier.
9. The method of claim 1 , wherein the bipolar disorder is bipolar I disorder, bipolar II disorder, cyclothymia, mixed bipolar disorder, rapid-cycling bipolar disorder, hypomania, dysthymia, or acute mania.
10. The method of claim 3 , wherein the steady state plasma concentration of latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, is from about 1 pg/ml to about 500 pg/ml.
11. The method of claim 3 , wherein the steady state plasma concentration of latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, is from about 500 pg/ml to about 1 ng/ml.
12. The method of claim 3 , wherein the steady state plasma concentration of latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, is from about 1 ng/ml to about 10 ng/ml.
13. The method of claim 5 , wherein the latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, is present in the pharmaceutical composition at a concentration of from about 0.001% to about 0.2% (w/v).
14. The method of claim 13 , wherein the latanoprost, travoprost or bimatoprost, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, is present in the pharmaceutical composition at a concentration of from about 0.001% to about 0.02% (w/v).